• Marie Ryan, Tatiana Zaldívar Vaillant, Russell L McLaughlin, Mark A Doherty, James Rooney, Mark Heverin, Joel Gutierrez, Gloria Esther Lara-Fernández, Mariana Pita Rodríguez, Jochen Hackembruch, Abayubá Perna, Maria Cristina Vazquez, Marco Musio, Carlos N Ketzoian, Giancarlo Logroscino, and Orla Hardiman.
• Academic Unit of Neurology, Trinity College Dublin, Dublin, Ireland ryanm65@tcd.ie.
• J. Neurol. Neurosurg. Psychiatr. 2019 Jun 1; 90 (6): 659-665.

ObjectivesThis study compares the clinical characteristics of patients with amyotrophic lateral sclerosis (ALS) within three clinic-based populations from Cuba, Uruguay and Ireland and determines the impact of known ALS-associated genetic variants on phenotypic manifestations within the Cuban population.MethodsDemographic and clinical information was collected on 115 Cuban, 220 Uruguayan and 1038 Irish patients with ALS attending national specialist clinics through 1996-2017. All Cuban patients and 676 Irish patients underwent next-generation DNA sequencing and were screened for the pathogenic C9orf72 repeat expansion.ResultsThe mean age of onset was younger in the Cuban (53.0 years, 95% CI 50.4 to 55.6) and Uruguayan (58.2 years, 95% CI 56.5 to 60.0) populations compared with the Irish population (61.6 years, 95% CI 60.9 to 62.4). No differences in survival between populations were observed. 1.7 % (95% CI 0.6 to 4.1) of Cubans with ALS carried the C9orf72 repeat expansion compared with 9.9% (95% CI 7.8 to 12.0) of Irish patients with ALS (p=0.004). Other known variants identified in the Cuban population included ANG (one patient), CHCHD10 (one patient) and DCTN1 (three patients).Conclusions And RelevanceThis study is the first to describe the clinical characteristics of ALS in Cuban and Uruguayan populations and report differences between the Cuban and Irish genetic signature in terms of known ALS-associated genetic variants. These novel clinical and genetic data add to our understanding of ALS across different and understudied populations.© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

19 keywords...

hide…